Healthcare-Associated Infections
DZIF scientists aim to develop new strategies against the development and spread of antibiotic resistance.
Antimicrobial resistance is one of the greatest challenges facing modern medicine worldwide. Bacterial pathogens from the so-called ESKAPE group, which frequently cause severe and difficult-to-treat infections, are particularly problematic. These include methicillin-resistant Staphylococcus aureus (MRSA), extended-spectrum beta-lactamase-producing Enterobacterales (ESBL-producers), carbapenemase-producing Enterobacterales (CPE), vancomycin-resistant enterococci (VRE), hypervirulent Klebsiella pneumoniae, and Pseudomonas aeruginosa, among others. Many of these infections occur in the context of medical treatment and develop during a stay in healthcare facilities.
The research area "Healthcare-Associated Infections" addresses three key challenges:
- Progressing antimicrobial resistance facing restricted treatment options
The global rise in resistant pathogens significantly complicates the treatment of infections. While fewer effective antibiotics are available, existing treatments must be preserved through responsible use and supplemented by new therapeutic strategies.
- Delayed or insufficient diagnostics
Conventional diagnostic procedures often take a long time until the results are available. This hinders targeted treatment and encourages the use of broad-spectrum antibiotics.
- Inadequate understanding of transmission and individual risks
The dynamics of resistance development and transmission between patients, facilities, and sectors are not well understood. Longitudinal and cross-sectoral analyses of integrated clinical and microbiological data are necessary to identify risk profiles and tailor targeted prevention strategies.
To address the global challenge of antimicrobial resistance (AMR), the research area "Healthcare-Associated Infections" focuses on three central themes:
Central Themes
-
Development and optimization of diagnostic methods
-
Innovative anti-infective therapies
-
Novel therapeutic approaches, including antibiotic combinations and bacteriophage-based therapies, as well as evolution- and microbiome-based strategies, aim to preserve the effectiveness of existing antibiotics and expand treatment options.
-
Personalized prevention
-
Longitudinal and cross-sector analyses of clinical, microbiological, and epidemiological data support the identification of individual risk profiles and the development of targeted prevention strategies based on a One Health approach.